開鬱二陳湯이 Estradiol Valerate로 유도된 흰쥐의 다낭성 난소 발달에 미치는 영향

키워드

참고문헌 (59)

1. 대한산부인과학회 교과서편찬위원회, "부인과학", pp.362~ (2007), 고려의학
2. 이혜진, "다낭난소증후군의 진단과 치료", 대한내분비학회지, 22(4), pp.252~256 (2007), 대한내분비학회
3. 김정훈, "다낭성난소증후군 치료의 최신지견", Korean Journal of Obstetrics and Gynecology, 48(8), pp.1851~1869 (2005), 대한산부인과학회
4. Krysiak R, "Update on the management of polycystic ovary syndrome", Pharmacological Reports, 58(5), pp.614~625 (2006)
5. 김동일, "다낭성 난소증후군에 관한 문헌적 고찰", 대한한방부인과학회지, 10(1), pp.73~91 (1997)
6. 吳桂芳, "中醫學治療多囊卵巢綜合症硏究槪況", 河南中醫, 14(2), pp.123~125 (1994)
7. 金維新, "不孕症的診斷與中醫治療", pp.172~177 (1992), 科學出版社
8. 萬全, "萬氏婦人科", pp.9~10 (1983), 湖北人民出版社
9. Brawer JR, "Development of the polycystic ovarian condition(PCO) in the estradiol valerate -treated rat", Biology of Reproduction, 35, pp.647~655 (1986)
10. Brawer JR, "Effects of a single injection of estradiol valerate on the hypothalamic arcuate nucleus and on reproductive function in the female rat", Endocrinology, 103, pp.501~512 (1978)
11. Stener VE, "Rats with steroid -induced polycystic ovaries develop hypertension and increased sympathetic nervous system activity", Reproductive Biology and Endocrinology, 3~44 (2005)
12. Polson　DW, "Polycystic ovaries-a common finding in normal women", The Lancet, 1, pp.870~872 (1988)
13. Balen AH, "Ultrasound assessment of the polycystic ovary:international consensus definitions", Human Reproduction Update, 9, pp.505~514 (2003)
14. 김 탁, "다낭성 난소 증후군의 최신 지견", 대한산부인과학회 연수강좌, 31, pp.38~44 (2002)
15. 민응기, "다낭성 난소 증후군", Korean Journal of Obstetrics and Gynecology, 51(8), pp.805~819 (2008), 대한산부인과학회
16. Baillargeon JP., "Use of insulin sensitizers in polycystic ovarian syndrome", Current Opinion in Investigational Drugs, 6, pp.1012~1022 (2005)
17. Conway GS, "Effects of Luteinizing Hormone, Insulin, Insulin-like Growth Factor-Ⅰ and Insulin-like Growth Factor Small Binding Protein 1 in the Polycystic Ovary Syndrome", Clinical Endocrinology, 33, pp.596~603 (1990)
18. 김세련, "고인슐린 혈증과 다낭성난소증후군의 병태 생리", 관동의대학술지, 9(1), pp.89~98 (2005)
19. Zawadski JK, "Diagnostic criteria for polycystic ovary syndrome :towards a rational approach in Polycystic ovary syndrome. 3rd ed", pp.377~384 (1992), Blackwell Scientific Publication
20. "2003 consensus on diagnostic criteria and ling term health risks related to polycystic ovary syndrome", The Rotterdam ESHRE, 2004, pp.81, 19~25[DOI]
21. "The Rotterdam ESHRE", ASRM-Sponsored PCOS Consensus Workshop Group, 2004, pp.19 (2003), 41~47[DOI]
22. Azziz R, "Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline", Journal of Clinical Endocrinology & Metabolism, 91, pp.4237~4245 (2006)
23. Azziz R, "Androgen excess in women: experience with over 1000 consecutive patients", Journal of Clinical Endocrinology & Metabolism, 89, pp.453~462 (2004)
24. Lergo RS, "Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome", The American journal of medicine, 111, pp.607~613 (2001)
25. Carmina E, "Difference in body weight between American and Italian women with polycystic ovary syndrome :influence of the diet", Human Reproduction, 18, pp.2289~2293 (2003)
26. Hahn S, "Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine- Westphalia", Hormone and Metabolic Research, 37, pp.438~444 (2005)
27. DeUgarte CM, "Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment", Fertil and Steril, 83, pp.1454~1460 (2005)
28. Lergo RS, "A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome", Journal of Clinical Endocrinology & Metabolism, 93, pp.2694~2698 (1998)
29. Lergo RS, "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women", Journal of Clinical Endocrinology & Metabolism, 84, pp.165~169 (1999)
30. Rebar R, "Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome", Journal of Clinical Endocrinology & Metabolism, 57, pp.1320~1329 (1976)
31. Conway GS, "Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients", Clinical Endocrinology, 30, pp.459~470 (1989)
32. Anttila L, "Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease", Fertil and Steril, 55, pp.1057~1061 (1991)
33. Santbrink EJ, "Classification of normogonadotropic infertility:polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome", Fertil and Steril, 67, pp.452~458 (1997)
34. Arroyo A, "Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity", Journal of Clinical Endocrinology & Metabolism, 82, pp.3728~3733 (1997)
35. Taylor AE, "Determinants of abnormal gonadotropin secretion in clinical defined women woth polycystic ovary syndrome", Journal of Clinical Endocrinology & Metabolism, 82, pp.2248~2256 (1997)
36. 윤소영, "다낭성 난소증후군 환자의 한방 치료에 대한 임상적 고찰", 대한한방부인과학회지, 13(2), pp.437~451 (2000)
37. Stener VE, "Effects of eletro -acupuncture on nerve growth factor and ovarian morphology in rats with experimentally induced polycystic ovaries", Biology of Reproduction, 63(5), pp.1497~1503 (2000)
38. Stener VE, "Effects of electro -acupuncture on corticotropin-releasing factor in rats with experimentally- induced polycystic ovaries", Neuropeptides, 35(5), pp.227~231 (2001)
39. Stener VE., "Acupuncture in reproductive medicine: Overview and summary of recent studies", International Congress Series, 1238, pp.149~156 (2002)
40. Manni L, "Effects of exrecise on ovarian morphology and expression of nerve growth factor and α1-and β2-adrenergic receptors in rats with steroid-induced polycystic ovaries", Journal of Neuroendocrinology, 17, pp.846~858 (2005)
41. 양승정, "蒼附導痰湯이 estradiol valerate로 유발된 백서의 다낭성 난소에 미치는 影響", 대한한방부인과학회지, 15(2), pp.1~11 (2002), 대한한방부인과학회
42. 유영기, "腎氣丸合蒼附導痰湯이 Estradiol Valerate로 유도된 흰쥐의 다낭성 난소에 미치는 영향", 대한한방부인과학회지, 20(1), pp.77~92 (2007), 대한한방부인과학회
43. 남은정, "定經湯이 Estradiol Valerate로 유도된 흰쥐의 다낭성 난소에 미치는 영향", 대한한방부인과학회지, 20(1), pp.93~116 (2007), 대한한방부인과학회
44. 김희주, "蒼附六君湯이 Estradiol Valerate로 유도된 흰쥐의 다낭성 난소에 미치는 영향", 대한한방부인과학회지, 21(2), pp.1~16 (2008), 대한한방부인과학회
45. 이연경, "歸脾湯이 Estradiol Valerate로 유도된 흰쥐의 다낭성 난소에 미치는 영향", 대한한방부인과학회지, 21(3), pp.60~74 (2008), 대한한방부인과학회
46. 한의부인과학 편찬위원회, "한의부인과학(上)", pp.126~410 (2002), 정담
47. 전국한의과대학본초학교실, "본초학", pp.290~541 (2000), 영림사
48. 허 준, "동의보감", pp.290~362 (2002), 법인문화사
49. Barb CR, "Inhibition of ovulation and LH secretion in the gilt after treatment with ACTH or hydrocortisone", Journal of Reproduction and Fertility, 64(1), pp.85~92 (1982)
50. 김근우, "항(抗) Stress 실험에 관한 비교 연구", 동의신경정신과학회지, 8(1), pp.111~125 (1997)
51. Anderson E, "Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model: Hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles", Reproductive Biology, 249(1), pp.44~53 (1998)
52. Halaas JL, "Weight-reducing effects of the plasma protein encoded by the obese gene", Science, 269(5223), pp.543~546 (1995)
53. Levin N, "Decreased food intake does not completely account for adiposity reduction after ob protein infusion", Proceedings of the National Academy of Sciences of the United States of America, 93(4), pp.1726~1730 (1996)
54. Levi MR., "The nerve growth factor 35 years later", Science, 237, pp.1154~1162 (1987)
55. Dissen GA, "Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat", Endocrinology, 141(3), pp.1073~1081 (2000)
56. Aguado LI, "Ovarian β-adrenergic receptors during the onset of puberty: characterization, distribution, and coupling to steroidogenic responses", Endocrinology, 110(4), pp.1124~1132 (1982)
57. Dyer CA, "Norepinephrine amplifies human chorionic gonadotropin -stimulated androgen biosynthesis by ovarian theca-interstitial cells", Endocrinology, 116(4), pp.1645~1652 (1985)
58. Lala HE, "An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat", Endocrinology, 141, pp.1059~1072 (2000)
59. Schulster A, "Polycystic ovarian condition in estradiol valerate -treated rat: Spontaneous changes in characteristic endocrine features", Biology of Reproduction, 31, pp.587~593 (1984)

관련 논문AI추천